Literature DB >> 8863138

Nasal delivery of vaccines.

A J Almeida1, H O Alpar.   

Abstract

Only relatively recently the significance of inducing not only systemic immunity but also significant local immunity at susceptible mucosal surfaces has become appreciated. A new field of mucosal immunity has been established as information accumulates on mucosal-associated lymphoid tissue (MALT) and on its role in both local and systemic immune responses. This review describes the formation of vaccines to be delivered to one of MALT components, i.e. the nasal-associated lymphoid tissue (NALT), which bears some similarities with the Peyer's patches of the intestine. The association of antigens with adjuvants and particulate carriers such as microparticles, nanoparticles and liposomes is emphasised.

Mesh:

Substances:

Year:  1996        PMID: 8863138     DOI: 10.3109/10611869609015965

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  19 in total

1.  Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide): evaluation of antibody response after oral and nasal application in mice.

Authors:  T Jung; W Kamm; A Breitenbach; K D Hungerer; E Hundt; T Kissel
Journal:  Pharm Res       Date:  2001-03       Impact factor: 4.200

2.  Novel chitosan particles and chitosan-coated emulsions inducing immune response via intranasal vaccine delivery.

Authors:  Takahiro Nagamoto; Yoshiyuki Hattori; Kozo Takayama; Yoshie Maitani
Journal:  Pharm Res       Date:  2004-04       Impact factor: 4.200

3.  DNA vaccine expressing herpes simplex virus 1 glycoprotein C and D protects mice against herpes simplex keratitis.

Authors:  Li-Li Dong; Ru Tang; Yu-Jia Zhai; Tejsu Malla; Kai Hu
Journal:  Int J Ophthalmol       Date:  2017-11-18       Impact factor: 1.779

4.  The involvement of NK cell activation following intranasal administration of CpG DNA lipoplex in the prevention of pulmonary metastasis and peritoneal dissemination in mice.

Authors:  Shuwen Zhou; Shigeru Kawakami; Yuriko Higuchi; Fumiyoshi Yamashita; Mitsuru Hashida
Journal:  Clin Exp Metastasis       Date:  2011-11-04       Impact factor: 5.150

5.  In vitro evaluation of microparticles and polymer gels for use as nasal platforms for protein delivery.

Authors:  C Witschi; R J Mrsny
Journal:  Pharm Res       Date:  1999-03       Impact factor: 4.200

6.  Trachea, lung, and tracheobronchial lymph nodes are the major sites where antigen-presenting cells are detected after nasal vaccination of mice with human papillomavirus type 16 virus-like particles.

Authors:  Carole Balmelli; Stéphane Demotz; Hans Acha-Orbea; Pierre De Grandi; Denise Nardelli-Haefliger
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

7.  Stealth PLA-PEG nanoparticles as protein carriers for nasal administration.

Authors:  M Tobío; R Gref; A Sánchez; R Langer; M J Alonso
Journal:  Pharm Res       Date:  1998-02       Impact factor: 4.200

Review 8.  Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells.

Authors:  Kwang-Chul Kwon; Dheeraj Verma; Nameirakpam D Singh; Roland Herzog; Henry Daniell
Journal:  Adv Drug Deliv Rev       Date:  2012-10-23       Impact factor: 15.470

9.  Evaluation of mucoadhesive PLGA microparticles for nasal immunization.

Authors:  Dilip Pawar; Amit K Goyal; Sharad Mangal; Neeraj Mishra; Bhuvaneshwar Vaidya; Shailja Tiwari; Arvind K Jain; Suresh P Vyas
Journal:  AAPS J       Date:  2010-01-15       Impact factor: 4.009

10.  Chimeric plant virus particles administered nasally or orally induce systemic and mucosal immune responses in mice.

Authors:  F R Brennan; T Bellaby; S M Helliwell; T D Jones; S Kamstrup; K Dalsgaard; J I Flock; W D Hamilton
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.